title: Triptans: where things stand.
abstract: Triptans, selective serotonin receptor agonists, were developed almost 20 years ago and represented a major breakthrough in the treatment of acute migraine attacks. Since then, the triptans have become first-line agents for most patients with migraine, both with and without aura, unless contraindicated. This article reviews the development of triptans, discusses reasons for their success or failure, and examines the limitations and controversies surrounding this class of medication.
authors.affiliation: Thomas Jefferson University, 111 South 11th Street, Suite 8130, Philadelphia, PA, 19107, USA.
authors.forename: Alan K
authors.initials: AK
authors.lastname: Cole
authors.forename: Michael J
authors.initials: MJ
authors.lastname: Marmura